Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $9.60 Average Target Price from Analysts

Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) have been given a consensus recommendation of “Hold” by the six research firms that are currently covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $9.60.

Several analysts have recently commented on VRCA shares. Royal Bank of Canada cut Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating and reduced their price target for the company from $11.00 to $2.00 in a report on Tuesday, November 5th. Needham & Company LLC reissued a “hold” rating on shares of Verrica Pharmaceuticals in a report on Tuesday, November 5th. HC Wainwright downgraded shares of Verrica Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 6th. TD Cowen decreased their target price on shares of Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, October 21st. Finally, Brookline Capital Management reiterated a “hold” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, October 2nd.

Institutional Trading of Verrica Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in VRCA. Barclays PLC lifted its position in shares of Verrica Pharmaceuticals by 404.6% during the 3rd quarter. Barclays PLC now owns 31,341 shares of the company’s stock worth $45,000 after purchasing an additional 25,130 shares during the last quarter. Quest Partners LLC acquired a new stake in Verrica Pharmaceuticals during the second quarter worth $50,000. Key Financial Inc bought a new stake in Verrica Pharmaceuticals in the second quarter valued at about $69,000. Verition Fund Management LLC acquired a new position in shares of Verrica Pharmaceuticals in the 3rd quarter worth approximately $89,000. Finally, Jane Street Group LLC raised its stake in Verrica Pharmaceuticals by 106.5% during the third quarter. Jane Street Group LLC now owns 69,872 shares of the company’s stock worth $101,000 after acquiring an additional 36,028 shares in the last quarter. Institutional investors and hedge funds own 42.45% of the company’s stock.

Verrica Pharmaceuticals Stock Up 11.6 %

Shares of NASDAQ:VRCA opened at $0.99 on Friday. The firm has a market capitalization of $45.14 million, a PE ratio of -0.54 and a beta of 1.45. Verrica Pharmaceuticals has a 1 year low of $0.70 and a 1 year high of $11.41. The company has a debt-to-equity ratio of 29.58, a current ratio of 1.34 and a quick ratio of 1.22. The firm’s 50-day moving average is $1.39 and its two-hundred day moving average is $4.72.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its quarterly earnings data on Monday, November 4th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.12). The business had revenue of ($1.78) million during the quarter, compared to analysts’ expectations of $7.53 million. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. Analysts predict that Verrica Pharmaceuticals will post -1.42 EPS for the current year.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.